Literature DB >> 20051941

High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations.

M G F van Lier1, A Wagner, E M H Mathus-Vliegen, E J Kuipers, E W Steyerberg, M E van Leerdam.   

Abstract

OBJECTIVES: Peutz-Jeghers syndrome (PJS) is an autosomal dominant inherited disorder associated with increased cancer risk. Surveillance and patient management are, however, hampered by a wide range in cancer risk estimates. We therefore performed a systematic review to assess cancer risks in PJS patients and used these data to develop a surveillance recommendation.
METHODS: A systematic PubMed search was performed up to February 2009, and all original articles dealing with PJS patients with confirmed cancer diagnoses were included. Data involving cancer frequencies, mean ages at cancer diagnosis, relative risks (RRs), and cumulative risks were collected.
RESULTS: Twenty-one original articles, 20 cohort studies, and one meta-analysis fulfilled the inclusion criteria. The cohort studies showed some overlap in the patient population and included a total of 1,644 patients; 349 of them developed 384 malignancies at an average age of 42 years. The most common malignancy was colorectal cancer, followed by breast, small bowel, gastric, and pancreatic cancers. The reported lifetime risk for any cancer varied between 37 and 93%, with RRs ranging from 9.9 to 18 in comparison with the general population. Age-related cumulative risks were given for any cancer and gastrointestinal, gynecological, colorectal, pancreatic, and lung cancers.
CONCLUSIONS: PJS patients are markedly at risk for several malignancies, in particular gastrointestinal cancers and breast cancer. On the basis of these elevated risks, a surveillance recommendation is developed to detect malignancies in an early phase and to remove polyps that may be premalignant and may cause complications, so as to improve the outcome.

Entities:  

Mesh:

Year:  2010        PMID: 20051941     DOI: 10.1038/ajg.2009.725

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  146 in total

1.  Genetic susceptibility to pancreatic cancer.

Authors:  Alison P Klein
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 2.  The role of LKB1 in lung cancer.

Authors:  Montse Sanchez-Cespedes
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

3.  The tumor suppressor LKB1 antagonizes WNT signaling pathway through modulating GSK3β activity in cell growth of esophageal carcinoma.

Authors:  Kai Liu; Yue Luo; Hui Tian; Kai-Zhong Yu; Jin-Xian He; Wei-Yu Shen
Journal:  Tumour Biol       Date:  2014-02

4.  Familial gastric cancer: update for practice management.

Authors:  Giovanni Corso; Daniele Marrelli; Franco Roviello
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

Review 5.  Management of Advanced Small Bowel Cancer.

Authors:  Alberto Puccini; Francesca Battaglin; Heinz-Josef Lenz
Journal:  Curr Treat Options Oncol       Date:  2018-11-05

Review 6.  Hereditary diffuse gastric cancer: What the clinician should know.

Authors:  Ryan Ying Cong Tan; Joanne Ngeow
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

7.  Lkb1/Stk11 regulation of mTOR signaling controls the transition of chondrocyte fates and suppresses skeletal tumor formation.

Authors:  Lick Pui Lai; Brendan N Lilley; Joshua R Sanes; Andrew P McMahon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

8.  Peutz-Jeghers syndrome with early onset of pre-adolescent gynecomastia: a predigree case report and clinical and molecular genetic analysis.

Authors:  Long-Jiang Zhang; Zhe Su; Xia Liu; Li Wang; Qin Zhang
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

9.  Lkb1 deletion in murine B lymphocytes promotes cell death and cancer.

Authors:  George P Souroullas; Yuri Fedoriw; Louis M Staudt; Norman E Sharpless
Journal:  Exp Hematol       Date:  2017-04-21       Impact factor: 3.084

Review 10.  Identifying people at a high risk of developing pancreatic cancer.

Authors:  Alison P Klein
Journal:  Nat Rev Cancer       Date:  2012-12-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.